List of Excipients in Branded Drug PERMETHRIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Renaissance Pharma Inc	PERMETHRIN	permethrin	40085-615	BUTYLATED HYDROXYTOLUENE
Renaissance Pharma Inc	PERMETHRIN	permethrin	40085-615	CARBOMER HOMOPOLYMER TYPE B
Renaissance Pharma Inc	PERMETHRIN	permethrin	40085-615	FORMALDEHYDE
Renaissance Pharma Inc	PERMETHRIN	permethrin	40085-615	GLYCERIN

Generic Drugs Containing PERMETHRIN

Company	Ingredient	NDC	Excipient
Actavis Pharma Inc	permethrin	0472-0242	BUTYLATED HYDROXYTOLUENE
Actavis Pharma Inc	permethrin	0472-0242	CARBOMER 934
Actavis Pharma Inc	permethrin	0472-0242	CETETH-10
Actavis Pharma Inc	permethrin	0472-0242	CETETH-20

What are the Most Frequently-Used Excipients in PERMETHRIN?

# Of NDCs	Excipient
1	ANHYDROUS CITRIC ACID
1	BALSAM FIR LEAFY TWIG
17	BUTYLATED HYDROXYTOLUENE
1	BUTYLPARABEN

Permethrin Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Permethrin is a mature, low-cost pyrethroid with two principal pharmaceutical markets: 5% topical cream for scabies and 1% topical lotion or rinse for head lice. The active ingredient has limited composition-of-matter and exclusivity value because its core patents expired decades ago. Commercial differentiation therefore depends on excipient selection, product usability, regulatory positioning, packaging, and channel economics.

The strongest opportunities are low-irritation pediatric products, cosmetically improved lice treatments, stable ready-to-use formulations, preservative-minimized systems, and combination or adherence-oriented products. Excipient patents can protect formulation architecture, but they are more likely to face obviousness and freedom-to-operate challenges than patents covering novel chemical entities.

What pharmaceutical formulations contain permethrin?

Permethrin is used in several dosage forms and concentration ranges.

Product category	Typical concentration	Route	Principal use	Regulatory status
Scabies cream	5% w/w	Topical	Scabies infestation	Prescription drug
Head-lice lotion or rinse	1% w/w	Topical	Pediculosis capitis	OTC drug under FDA monograph framework
Veterinary topical products	Varies	Topical	Fleas, ticks, mites and lice	Animal drug or pesticide, depending on product
Agricultural and household products	Varies	Non-pharmaceutical	Crop and pest control	EPA pesticide regulation

The 5% cream is generally applied from the neck downward and washed off after a defined contact period. The 1% product is applied to hair and scalp and removed after treatment. These different use conditions create separate excipient requirements.

Permethrin is lipophilic and practically insoluble in water. Formulators commonly use an oil-in-water cream, emulsion, lotion, suspension, or rinse system to distribute the active across skin or hair. The formulation must maintain uniform active concentration without creating excessive greasiness, odor, residue, or irritation.

What excipients are used in permethrin products?

Commercial labels identify excipients that support emulsion stability, skin feel, viscosity, preservation, and wash-off performance.

Typical 5% cream excipients

Permethrin 5% creams commonly use:

• Cetyl alcohol and stearyl alcohol as fatty alcohol structuring agents and emulsion stabilizers.
• Isopropyl myristate as an emollient and spreading aid.
• Glycerin or glycerol as a humectant.
• Water as the continuous phase.
• Carbomer, xanthan gum, or similar polymers for viscosity control.
• Polysorbates or other surfactants for emulsion stability.
• Preservatives or chelating agents where required by the formulation.

The formulation target is a smooth cream that spreads over large skin areas and remains in place during the treatment period. Excessive occlusion may increase discomfort, while insufficient viscosity can cause run-off and underdosing.

Typical 1% lotion and rinse excipients

Head-lice products need different performance characteristics. Important excipient functions include:

• Wetting the hair and scalp quickly.
• Maintaining contact during the treatment interval.
• Avoiding heavy oiliness or difficult comb-out.
• Allowing removal with ordinary shampoo or water.
• Minimizing sting on excoriated scalp.
• Preserving the product through repeated consumer use.

Lotion systems may contain alcohols, glycols, surfactants, thickeners, film-forming polymers, fragrances, and preservatives. The exact composition differs among manufacturers and may change when a product is reformulated or transferred to a new manufacturer.

How should an excipient strategy be designed for permethrin?

An effective strategy begins with the treatment site rather than the active ingredient.

Scabies cream strategy

For 5% scabies cream, the main formulation objectives are:

1. High and uniform drug distribution across the skin.
2. Adequate residence time during the application period.
3. Low irritancy on inflamed or excoriated skin.
4. Simple removal after treatment.
5. Physical and chemical stability across the intended shelf life.
6. Acceptable texture for full-body application.

A conventional oil-in-water cream is commercially defensible because it uses familiar excipients and supports a conventional generic pathway. The main weakness is limited differentiation. A new product may improve usability through lower greasiness, faster spreading, reduced residue, or a more neutral odor.

A preservative-minimized or preservative-free cream may have value for patients with dermatitis, infants where permitted by labeling, and consumers concerned about excipient sensitivity. The commercial benefit must be balanced against microbial risk, container-closure performance, and stability testing.

Head-lice formulation strategy

For 1% lice products, excipient selection should focus on hair performance and treatment completion. Consumers often judge the product by smell, residue, rinsability, and ease of combing rather than by pharmacologic attributes.

Potential design choices include:

• A low-oil lotion with rapid scalp coverage.
• A conditioning system that reduces tangling during nit combing.
• A washable emulsion with reduced odor.
• A low-foam system that improves product control.
• A unit-dose package that reduces underapplication.
• A pump or metered dispenser that simplifies dosing.
• A pediatric-oriented formulation with reduced sting and no unnecessary fragrance.

A formulation that improves adherence without changing the active ingredient may have a stronger commercial proposition than a technically complex delivery system.

What formulation patents could protect permethrin products?

Permethrin formulation patents may cover:

• Specific oil-to-water ratios.
• Surfactant combinations.
• Polymer-thickened emulsions.
• Microemulsions or nanoemulsions.
• Encapsulated permethrin.
• Controlled-release particles.
• Low-irritation systems.
• Preservative-free formulations.
• Hair-conditioning compositions.
• Combination products containing permethrin and another antiparasitic.
• Particular packaging and dispensing systems.
• Manufacturing processes that improve particle size, uniformity, or stability.

The strongest patent position generally requires more than listing known excipients. A patent is more defensible when it claims a defined composition tied to measurable performance, such as improved stability, lower irritation, improved wash-off, enhanced deposition, reduced odor, or better treatment outcomes.

Broad claims covering "permethrin with a pharmaceutically acceptable excipient" are vulnerable because topical emulsions, fatty alcohols, surfactants, humectants, and viscosity agents are established formulation tools.

Manufacturing and process protection

Process claims can provide practical protection where the formulation is difficult to manufacture consistently. Potential claim areas include:

• Controlled addition order for oil and aqueous phases.
• Temperature-controlled emulsification.
• Homogenization conditions.
• Particle-size control.
• Deaeration and filling.
• Control of polymorphic or crystallized permethrin.
• In-process assay uniformity.
• Packaging that limits evaporation or phase separation.

Manufacturing patents have commercial value when they reduce batch failures or enable a stable formulation with fewer excipients. They are less valuable if a competitor can reach the same product through an ordinary process.

What is the FDA regulatory status of permethrin?

Permethrin has different regulatory pathways depending on concentration and indication.

Prescription scabies products

Permethrin 5% cream is regulated as a prescription drug for scabies. The reference product, Elimite, established the relevant U.S. prescription market, while generic products have entered through abbreviated new drug applications.

For a generic 5% cream, the sponsor generally must demonstrate pharmaceutical equivalence and bioequivalence under FDA requirements. Topical dermatologic products may require product-specific testing, comparative characterization, or clinical endpoint studies depending on the FDA pathway and product guidance.

OTC head-lice products

Permethrin 1% lice products are marketed under the FDA OTC topical pediculicide framework. FDA regulations identify permethrin as an active ingredient for this use under 21 C.F.R. Part 358, Subpart F. The active ingredient is not protected by new chemical entity exclusivity in this setting.

OTC opportunities depend on compliance with the monograph conditions, labeling requirements, manufacturing controls, and applicable safety standards. A materially different dosage form, indication, concentration, or combination may require an FDA application rather than simple monograph marketing.

Product-specific regulatory risks

Excipient changes can affect regulatory status when they alter:

• Drug release or availability.
• Skin penetration.
• Residual activity.
• Irritation or sensitization.
• Microbial quality.
• Product performance under use conditions.
• Label directions or treatment contact time.

A reformulation that changes excipients but preserves the active concentration may still require substantial comparative data. The regulatory burden rises when the new formulation claims faster action, improved efficacy, reduced resistance, or a new patient population.

What is the Orange Book status of permethrin?

Permethrin products may appear in FDA drug databases and approved-product records, but Orange Book value is limited compared with newer prescription drugs.

The key commercial points are:

• The active ingredient is old and lacks meaningful remaining composition-of-matter exclusivity.
• Generic 5% creams are the principal prescription competitors.
• Any listed patents would be product-specific rather than foundational permethrin patents.
• Patent certifications and Paragraph IV disputes depend on the specific reference-listed product and patents listed at the time of an ANDA filing.
• OTC 1% products marketed under the monograph are not managed through the same Orange Book patent framework as a novel prescription product.

A prospective entrant should verify current FDA listings, reference-product status, patent listings, and exclusivity records before relying on any Orange Book conclusion. The commercial thesis should not depend on a patent barrier unless a current, enforceable, product-specific patent is confirmed.

When does permethrin lose exclusivity?

Permethrin's core exclusivity has already expired. It is a mature generic active ingredient.

Exclusivity category	Current commercial relevance
Compound patent	Expired
Basic composition patent	Expired or commercially immaterial
Prescription exclusivity	Expired for the historical reference product
OTC monograph access	Available subject to monograph compliance
Formulation patents	Possible, but narrow and product-dependent
Method-of-use patents	Possible for new indications or regimens, but uncommon for standard scabies and lice use
Regulatory exclusivity for a new formulation	Possible only if a qualifying application and statutory criteria apply

A new formulation could obtain patents or regulatory exclusivity based on its formulation, indication, or clinical evidence. That protection would not extend to ordinary permethrin products that do not practice the protected claims.

What generic entry risks exist for permethrin?

Generic entry risk is high for standard 5% creams and 1% lice products because:

• The active ingredient is inexpensive.
• Manufacturing technology is conventional.
• Multiple excipient systems can deliver a topical cream or lotion.
• Patients and payers often prioritize price.
• Prescribers have limited brand loyalty for routine scabies treatment.
• OTC consumers can switch rapidly among products.

The main barriers are not active-ingredient patents. They are regulatory execution, product quality, supply reliability, pharmacy distribution, brand recognition, and consumer acceptance.

A formulation patent can delay direct copying but may not stop noninfringing alternatives. A competitor may use different emulsifiers, polymers, preservatives, or packaging while delivering a substantially similar product.

Which commercial opportunities are strongest?

Pediatric and sensitive-skin products

Products designed for sensitive skin can command a premium if they reduce sting, odor, greasiness, or residue. Claims must remain within the supported regulatory framework. "Fragrance-free," "low-odor," "preservative-free," and "dermatologist tested" positioning may be commercially useful but require substantiation and careful labeling.

Improved lice-treatment experience

The OTC lice market has greater room for consumer differentiation than the prescription scabies market. Opportunities include:

• Easier application to dense or long hair.
• Improved nit-combing performance.
• Better rinsability.
• Reduced oily residue.
• Unit-dose packaging.
• Child-resistant but convenient packaging.
• Formulations compatible with frequent retreatment instructions.

The product must avoid implying that excipient improvements overcome documented resistance unless supported by evidence.

Combination products

Permethrin could be paired with another antiparasitic, ovicidal agent, or supportive ingredient. Combination development faces higher regulatory and clinical costs. The commercial case is strongest where the combination addresses treatment failure, resistance, or incomplete adherence.

A combination with a second active ingredient may create new patent opportunities, but it also increases safety, compatibility, stability, and regulatory complexity.

Regional and emerging-market supply

Permethrin is widely used in regions with substantial scabies and lice burden. Commercial opportunities include:

• Affordable single-use sachets.
• Heat-stable products for weak cold-chain environments.
• High-yield tubes for institutional treatment.
• Local contract manufacturing.
• Hospital and public-health tenders.
• Products adapted to local hair types and washing practices.

Geographic protection is likely to come from trademarks, packaging, regulatory registrations, manufacturing know-how, and distribution rather than from broad active-ingredient patents.

How does permethrin compare with competing antiparasitic products?

Attribute	Permethrin	Ivermectin topical/oral	Spinosad topical	Benzyl alcohol lotion
Primary uses	Scabies, lice	Scabies, lice in selected settings	Head lice	Head lice
Active-ingredient maturity	Very mature	Mature but broader product innovation	More recent topical positioning	Mature
Main formulation issue	Emulsion, spreadability, residue	Solubilization and skin delivery	Vehicle compatibility and stability	Solvent irritation and application
Generic pressure	High	Variable by product	Product-dependent	High
Excipient opportunity	Texture, irritation, wash-off, packaging	Delivery and tolerability	Cosmetic profile and stability	Irritation reduction
Patent leverage	Mostly formulation-specific	Product and formulation-specific	Product-specific	Limited

Permethrin's cost advantage is substantial, but its clinical and commercial position can weaken where resistance, retreatment, or treatment adherence is a concern. A superior excipient system can improve product experience but cannot by itself solve active resistance.

What patent litigation and Paragraph IV risks affect permethrin?

There is no broad, current patent barrier around permethrin itself. Paragraph IV risk would arise from a generic applicant challenging an unexpired patent listed for a particular prescription product, such as a formulation or method-of-use patent.

For a mature permethrin product, likely litigation issues include:

• Whether the asserted claims cover the generic's excipient system.
• Whether the patent claims are obvious over established topical formulations.
• Whether the patent covers a clinically meaningful formulation feature.
• Whether the generic can launch at risk.
• Whether a settlement restricts launch timing or product design.

Settlement value is generally limited where multiple noninfringing formulations are available and payer substitution is high. A patent owner may have more leverage if its product has a differentiated label, strong distribution, or a formulation that is difficult to reproduce without infringement.

How strong is the permethrin patent estate?

The foundational patent estate is weak because permethrin is an old active ingredient. The commercially relevant estate is formulation-specific and generally narrow.

Patent layer	Relative strength
Permethrin molecule	Very weak or expired
Standard 5% cream	Weak unless tied to a specific formulation or process
Standard 1% lotion	Weak unless tied to a specific formulation or package
Novel delivery system	Moderate if supported by unexpected performance
Combination therapy	Moderate to strong if clinically differentiated
Manufacturing process	Moderate where process constraints are difficult to design around
Packaging and dosing	Usually narrow but commercially useful

A diligence review should focus on claim construction, prosecution history, terminal disclaimers, patent-family coverage, continuation status, and jurisdiction-specific validity. Patent expiration dates should be calculated from the earliest effective nonprovisional filing date, adjusted for patent-term adjustment, patent-term extension, terminal disclaimers, and applicable transitional rules.

Key Takeaways

• Permethrin's active-ingredient exclusivity has expired, leaving formulation and execution as the main sources of value.
• The 5% scabies cream market favors low-cost, reliable, low-irritation formulations.
• The 1% head-lice market offers greater room for consumer-facing differentiation.
• Excipient choices should target spreadability, residence time, wash-off, odor, hair conditioning, and irritation.
• Preservative-minimized, fragrance-free, low-residue, and unit-dose products have the clearest commercial positioning.
• Formulation patents must claim a defined composition or measurable performance advantage, not merely a conventional excipient list.
• Generic entry risk is high for ordinary permethrin creams and lotions.
• Manufacturing know-how, packaging, regulatory registrations, distribution, and brand positioning may be more valuable than broad patent claims.
• No biosimilar pathway applies because permethrin is a small-molecule drug, not a biologic.
• Combination products and delivery systems offer the largest potential for new patent protection but carry higher regulatory and development costs.

FAQs

Can a new excipient make permethrin patentable?

Yes, but the patent would protect the specific formulation rather than permethrin itself. The claims need technical distinctions and evidence supporting unexpected stability, tolerability, delivery, or treatment performance.

Are preservative-free permethrin creams commercially viable?

They can be viable if the formulation and packaging control microbial risk. Airless pumps, unit-dose packaging, low-water systems, and validated manufacturing controls may support the strategy.

Can permethrin be reformulated as a foam?

A foam may improve coverage and reduce perceived greasiness, but it would require development of a compatible propellant or foaming system, dose-uniformity testing, container-closure studies, and appropriate FDA regulatory support.

Does permethrin have biosimilar competition?

No. Permethrin is a synthetic small-molecule active ingredient. Competition comes from generic drugs, OTC monograph products, and alternative antiparasitic treatments.

What is the most defensible commercial claim for a new permethrin product?

The strongest claim is usually a supported formulation or use benefit, such as improved wash-off, lower irritation, reduced residue, better hair conditioning, or easier dosing. Broad claims based only on combining permethrin with standard pharmaceutical excipients are less defensible.

References

1. U.S. Food and Drug Administration. (n.d.). Permethrin 5% cream prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Permethrin 1% lotion and lice treatment labeling. DailyMed. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (2024). Electronic Code of Federal Regulations, 21 C.F.R. Part 358: Skin protectant drug products for over-the-counter human use. https://www.ecfr.gov/

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book

5. U.S. Environmental Protection Agency. (2024). Permethrin pesticide registration and regulatory information. https://www.epa.gov/

6. World Health Organization. (2023). WHO guidelines for the treatment of scabies. World Health Organization. https://www.who.int/

7. U.S. Food and Drug Administration. (2024). Generic drug development and abbreviated new drug application requirements for topical products. https://www.fda.gov/drugs/generic-drugs/abbreviated-new-drug-application-anda-forms-and-instructions